Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 6Phase 3 3Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Completed 3Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 21INDUSTRY 6NIH 3

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 2Plasma cell 2Lymphoid 2Other hematologic neoplasm 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Acetaminophen × Clear all
NCT06788912 2026-05-26

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT04165096 2026-05-13

MK-3475-01C

Merck Sharp & Dohme LLC

Phase 2 Completed
128 enrolled 14 charts
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05704049 2025-12-29

IZALCO

Sanofi

Phase 2 Active not recruiting
118 enrolled
Plasma cell

Multiple Myeloma

NCT04660799 2023-10-12

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Hoffmann-La Roche

Phase 2 Completed
50 enrolled 25 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02999633 2022-03-21

ISLAY

Sanofi

Phase 2 Terminated
14 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01985126 2018-06-25

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Janssen Research & Development, LLC

Phase 2 Completed
124 enrolled 18 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡